 LA JOLLA, Calif.--BUSINESS WIRE--DermTech, Inc. NASDAQ: DMTK DermTech, a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective November 3, 2020, with Blue Cross Blue Shield of Illinois for its Commercial PPO and Medicare Advantage membership. DermTechs PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99 negative predictive value NPV, meaning 